Dimed SA Distribuidora de Medicamentos
BOVESPA:PNVL3
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.89
12.11
|
| Price Target |
|
We'll email you a reminder when the closing price reaches BRL.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Wall Street
Price Targets
PNVL3 Price Targets Summary
Dimed SA Distribuidora de Medicamentos
According to Wall Street analysts, the average 1-year price target for
PNVL3
is 12.92 BRL
with a low forecast of 12.12 BRL and a high forecast of 14.7 BRL.
Revenue
Forecast
Revenue Estimate
Dimed SA Distribuidora de Medicamentos
For the last 13 years the
compound annual growth rate for
Dimed SA Distribuidora de Medicamentos's revenue is
11%.
The projected
CAGR
for the next 4 years is
13%.
Operating Income
Forecast
Operating Income Estimate
Dimed SA Distribuidora de Medicamentos
For the last 13 years the
compound annual growth rate for
Dimed SA Distribuidora de Medicamentos's operating income is
10%.
The projected
CAGR
for the next 4 years is
16%.
Net Income
Forecast
Net Income Estimate
Dimed SA Distribuidora de Medicamentos
For the last 13 years the
compound annual growth rate for
Dimed SA Distribuidora de Medicamentos's net income is
8%.
The projected
CAGR
for the next 2 years is
44%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is PNVL3's stock price target?
Price Target
12.92
BRL
According to Wall Street analysts, the average 1-year price target for
PNVL3
is 12.92 BRL
with a low forecast of 12.12 BRL and a high forecast of 14.7 BRL.
What is Dimed SA Distribuidora de Medicamentos's Revenue forecast?
Projected CAGR
13%
For the last 13 years the
compound annual growth rate for
Dimed SA Distribuidora de Medicamentos's revenue is
11%.
The projected
CAGR
for the next 4 years is
13%.
What is Dimed SA Distribuidora de Medicamentos's Operating Income forecast?
Projected CAGR
16%
For the last 13 years the
compound annual growth rate for
Dimed SA Distribuidora de Medicamentos's operating income is
10%.
The projected
CAGR
for the next 4 years is
16%.
What is Dimed SA Distribuidora de Medicamentos's Net Income forecast?
Projected CAGR
44%
For the last 13 years the
compound annual growth rate for
Dimed SA Distribuidora de Medicamentos's net income is
8%.
The projected
CAGR
for the next 2 years is
44%.
